JAK2 Mutations in Myeloproliferative Neoplasms

by Kamran Mirza MBBS PhD FCAP
April 4, 2026

If your blood or bone marrow report mentions a JAK2 mutation — most often written as JAK2 V617F — this refers to a change in a gene that controls how blood cells are made in the bone marrow. JAK2 mutations are the most common molecular finding across the group of blood conditions called myeloproliferative neoplasms (MPNs). They are found in nearly all cases of polycythemia vera, and in about half of cases of essential thrombocythemia and primary myelofibrosis. A JAK2 mutation confirms the diagnosis of an MPN, helps determine which type you have, predicts how the disease may behave, and — in patients with myelofibrosis — identifies whether a group of targeted drugs called JAK inhibitors is likely to help. This article explains what JAK2 testing looks for, how to read the result, and what it means for your care.

What the test looks for

The JAK2 gene provides instructions for making a protein — also called JAK2 — that acts as a relay inside blood-forming cells. When the body needs more blood cells, hormones and growth signals bind to receptors on the cell surface. JAK2 sits just inside the cell wall and picks up that signal, passing it into the cell’s interior through a chain of events called the JAK-STAT pathway. Once the signal reaches the cell’s control center, the cell gets the message to grow and divide. When the body has enough red blood cells, the signal stops, and JAK2 is turned off.

In myeloproliferative neoplasms, a mutation in the JAK2 gene disrupts this off-switch. The protein stays permanently switched on — continuously telling blood-forming cells to grow and multiply, even when the body is not sending that signal. This is what leads to the overproduction of blood cells that characterize MPNs.

JAK2 V617F

The most common JAK2 mutation — present in about 95–97% of people with polycythemia vera and about 50–60% of people with essential thrombocythemia and primary myelofibrosis — is called JAK2 V617F. The name describes exactly what has changed: at position 617 in the JAK2 protein, one amino acid (valine, abbreviated V) has been swapped for a different one (phenylalanine, abbreviated F). This single swap is enough to lock the protein in a permanent position.

JAK2 exon 12 mutations

A smaller group of people with polycythemia vera — about 3–4% of PV cases, typically those who test negative for V617F — carry a different type of JAK2 mutation located in a region of the gene called exon 12. These mutations have the same effect — permanently switched-on JAK2 signaling — but are less common and are almost exclusively associated with polycythemia vera rather than the other MPNs. They produce a slightly different clinical picture: erythrocytosis (specifically, overproduction of red blood cells) is often more pronounced. In contrast, platelet and white blood cell counts may be less elevated than in V617F-positive PV.

Both V617F and exon 12 mutations are somatic — meaning they develop in a blood-forming stem cell during a person’s lifetime and are not inherited. They are not passed on to children and do not indicate a hereditary condition.

Why is the test done

JAK2 testing is done for three reasons: to confirm the diagnosis of an MPN, to distinguish between MPN subtypes, and to guide treatment decisions.

A JAK2 V617F mutation is one of the main criteria used to diagnose polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Finding it provides strong evidence that elevated blood counts or bone marrow changes are caused by an MPN rather than a reactive condition — meaning a temporary response to something else, such as infection or iron deficiency.

The test also helps distinguish between MPN subtypes. Polycythemia vera is almost always JAK2-positive, while essential thrombocythemia and primary myelofibrosis may be positive for JAK2, CALR, or MPL mutations, or occasionally none of these. The specific mutation found — or its absence — is one of the pieces of information used alongside the blood count picture and bone marrow examination to determine which MPN subtype is present.

For patients with significant myelofibrosis, JAK2 mutation status is part of the assessment for JAK inhibitor therapy — a group of drugs that directly block the overactive JAK2 protein.

Who should be tested

JAK2 testing is recommended for anyone whose blood tests or bone marrow findings suggest an MPN. This includes people with:

A persistently elevated red blood cell count, hemoglobin, or hematocrit is the main abnormality on blood tests in polycythemia vera.
A persistently high platelet count is the main feature of essential thrombocythemia.
Bone marrow scarring (fibrosis), anemia, or an enlarged spleen — features of primary myelofibrosis.
An unexplained blood clot in an unusual location — such as the portal vein, splenic vein, or hepatic veins. MPN-related blood clots can occur even when blood counts appear near-normal, and JAK2 testing should be considered in this setting.

JAK2 testing is also repeated when an MPN previously JAK2-negative is reassessed or when the clinical picture changes, prompting a fresh look at the diagnosis.

How the test is performed

JAK2 testing is usually performed on a blood sample. In some cases — particularly when a bone marrow biopsy has already been done for diagnosis — the bone marrow sample is used instead.

The most common method is PCR (polymerase chain reaction) — a technique that makes many copies of a specific region of the JAK2 gene and then checks whether the V617F mutation is present in those copies. PCR is highly sensitive and can detect the mutation even when only a small proportion of cells carry it.

Many centers also use next-generation sequencing (NGS) — a technology that reads the genetic code across many genes at once. NGS can detect V617F, along with exon 12 mutations and other clinically relevant changes in genes such as CALR, MPL, ASXL1, TET2, and SRSF2, in a single test. This comprehensive approach is particularly useful because the full combination of mutations present helps predict how an MPN is likely to behave over time.

How results are reported

Positive or negative

The basic result is reported as JAK2 V617F detected or not detected. If exon 12 testing was performed, the result will specify which mutation in exon 12 was found. A negative JAK2 result does not rule out an MPN — it means testing should also look for CALR and MPL mutations, which together account for most JAK2-negative MPNs.

The allele burden — a number that matters

When a JAK2 V617F mutation is detected, the report also includes a number called the allele burden, also known as variant allele frequency (VAF). This measures the proportion of JAK2 gene copies in the tested cells that carry the mutation.

Think of it this way: most of your cells carry two copies of every gene — one from each parent. In a blood-forming stem cell where the JAK2 V617F mutation has occurred, one of those two copies is mutated. As the stem cell divides and produces more cells, all its descendants carry the same mutation. The allele burden measures the percentage of JAK2 gene copies across the whole sample that are mutated. A result of 25% means that one in four JAK2 gene copies in the sample carries the mutation. A result of 75% means three in four carry it.

In simple terms, a higher allele burden generally means more of the blood-forming cells in the bone marrow are descended from the mutated clone — the group of abnormal cells that started with the original mutation. A very high allele burden in polycythemia vera, for example, is associated with a higher red blood cell count and a greater risk of blood clots. In myelofibrosis, a higher allele burden may be associated with more aggressive disease. Allele burden is also used to track treatment response — a falling allele burden during therapy is a sign that the treatment is reducing the number of abnormal cells.

You can read more about allele burden and variant allele frequency in the pathology dictionary.

What the result means

What a JAK2 mutation means in practice depends significantly on which MPN you have been diagnosed with. The sections below address each condition separately.

Polycythemia vera

In polycythemia vera, a JAK2 V617F or exon 12 mutation is found in virtually all patients and is one of the main diagnostic criteria. Finding it confirms that the elevated red blood cell count is being driven by an abnormal, permanently switched-on signal in the bone marrow — rather than by a secondary cause such as lung disease, smoking, or dehydration.

In polycythemia vera, the JAK2 mutation does not, by itself, determine how the disease is managed — blood count levels, age, and a history of blood clots are the main factors guiding treatment decisions. However, the allele burden provides some additional prognostic information. A higher allele burden is associated with higher blood counts, a larger spleen, and a somewhat greater risk of disease progression to myelofibrosis over time.

Treatment for polycythemia vera focuses on reducing the risk of blood clots and controlling blood counts, rather than directly targeting JAK2. This typically involves regular blood draws (phlebotomy) and low-dose aspirin, with cytoreductive drugs — medications that reduce red blood cell production — added for higher-risk patients. JAK inhibitor therapy with ruxolitinib is an option for patients whose disease is not adequately controlled with these approaches or whose symptoms are significantly affecting quality of life.

Essential thrombocythemia

In essential thrombocythemia, JAK2 V617F is found in about 50–60% of patients. The other approximately 40–50% carry CALR or MPL mutations, or occasionally none of these.

The specific mutation type in ET carries some prognostic significance. JAK2 V617F-positive ET is associated with a somewhat higher risk of blood clots compared to CALR-mutated ET. CALR-mutated ET tends to have a higher platelet count at diagnosis but a lower risk of clotting. These differences are taken into account when assessing an individual patient’s risk and deciding whether blood-thinning or cytoreductive treatment is needed.

A JAK2-negative result in a patient with a high platelet count and features of ET is not a reason to dismiss the diagnosis — it should prompt testing for CALR and MPL mutations. If all three are negative, the diagnosis can still be made based on blood and bone marrow findings. Still, the absence of any driver mutation places the patient in a category that may carry a more favorable prognosis.

Primary myelofibrosis

In primary myelofibrosis, JAK2 V617F is found in about 50–60% of patients, with CALR mutations accounting for most of the remaining cases, and MPL mutations found in a smaller proportion.

In myelofibrosis, the mutation type has meaningful prognostic implications. CALR type 1-mutated myelofibrosis generally carries the best outlook. JAK2 V617F-mutated myelofibrosis carries an intermediate prognosis. JAK2-negative, CALR-negative, MPL-negative myelofibrosis — sometimes called triple-negative — is generally associated with the most aggressive behavior and the shortest survival.

For patients with myelofibrosis who have significant symptoms — such as a large spleen, fatigue, night sweats, or weight loss — JAK inhibitors are the main targeted treatment option. These drugs work by fitting into the JAK2 protein and blocking it from sending its constant growth signal, even when the protein is mutated. With the signal blocked, the bone marrow slows its overproduction of abnormal cells, the spleen often shrinks, and symptoms improve.

Four JAK inhibitors are currently approved for myelofibrosis:

Ruxolitinib (Jakavi / Jakafi). The first JAK inhibitor approved for myelofibrosis and the most widely used. It reduces spleen size and improves symptoms in most patients who respond. In the COMFORT-I and COMFORT-II trials, ruxolitinib reduced spleen volume by at least 35% in approximately 40–42% of patients — an outcome seen in fewer than 1% of those on standard care. Ruxolitinib is approved for both intermediate and high-risk myelofibrosis and is active regardless of whether the JAK2, CALR, or MPL mutation is present, because all three mutations activate the same JAK-STAT pathway.
Fedratinib (Inrebic). A JAK2-selective inhibitor approved for intermediate and high-risk myelofibrosis, including patients who have previously been treated with ruxolitinib. In the JAKARTA trial, fedratinib reduced spleen volume by at least 35% in approximately 36% of patients.
Pacritinib (Vonjo). A JAK inhibitor specifically approved for patients with myelofibrosis and a very low platelet count (below 50,000 per microlitre) — a group for whom ruxolitinib and fedratinib are not suitable because they further reduce platelets. In the PERSIST-2 trial, pacritinib reduced spleen volume by at least 35% in approximately 18% of patients with low platelets, compared to 3% on standard care.
Momelotinib (Ojjaara). A JAK inhibitor approved for patients with myelofibrosis and anemia, a common and debilitating feature of advanced disease. Unlike ruxolitinib, momelotinib has a unique mechanism that can reduce the need for red blood cell transfusions while controlling the spleen. In the MOMENTUM trial, momelotinib improved symptoms and reduced transfusion dependence compared to danazol in patients previously treated with ruxolitinib.

The choice of JAK inhibitor depends on your platelet count, whether you have anemia, whether you have been treated before, and your overall health. Your hematologist will explain which option is most appropriate for you.

For eligible patients with high-risk myelofibrosis, allogeneic stem cell transplantation — using healthy blood-forming cells from a donor to replace the patient’s own bone marrow — remains the only treatment with the potential to produce long-term remission. JAK inhibitors are sometimes used to reduce spleen size and improve a patient’s condition before transplant.

JAK2 not detected

A negative JAK2 result does not rule out an MPN. In essential thrombocythemia and primary myelofibrosis, roughly 40–50% of patients carry CALR or MPL mutations instead of JAK2. In polycythemia vera, a JAK2-negative result should prompt testing specifically for exon 12 mutations, which can cause PV in patients who are V617F-negative.

If all driver mutations — JAK2, CALR, and MPL — are negative and the clinical and bone marrow findings still suggest an MPN, the diagnosis can still be made, but the absence of a driver mutation influences risk assessment and is important information for your hematologist.

JAK2 mutations and blood clots

One of the most important clinical consequences of a JAK2 mutation — across all three MPN subtypes — is an increased risk of blood clots. The abnormal blood cells produced by JAK2-driven MPNs are stickier and more prone to clotting than normal blood cells. This risk is highest in polycythemia vera but is also present in essential thrombocythemia and, to a lesser extent, myelofibrosis.

In some people, an MPN-related blood clot is the first sign of the disease — occurring even before blood counts have risen to clearly abnormal levels. If you have had an unexplained blood clot in an unusual location, your doctor may recommend JAK2 testing even if your blood counts look near-normal. The presence of a JAK2 mutation in this setting is important diagnostic information.

Managing clot risk is a central part of MPN treatment. Low-dose aspirin is used for most patients with polycythemia vera and many with essential thrombocythemia. Cytoreductive drugs — and, in some situations, JAK inhibitors — are added for higher-risk patients to bring blood counts closer to normal and reduce the risk of a clot.

Monitoring JAK2 over time

Once a JAK2 mutation has been identified, the allele burden can be tracked over time using regular blood tests. A rising allele burden may signal that the abnormal clone is expanding, which can occur during disease progression or when treatment becomes less effective. A falling allele burden during treatment with a JAK inhibitor or other cytoreductive therapy suggests the treatment is reducing the number of abnormal cells in the bone marrow.

Monitoring allele burden is particularly useful in myelofibrosis, where changes in JAK2 levels between assessments can help guide decisions about treatment changes or stem cell transplantation. In polycythemia vera and essential thrombocythemia, allele burden monitoring is less routinely used but may be incorporated in some treatment programs.

What happens next

For patients newly diagnosed with an MPN, a positive JAK2 result is part of a broader assessment that includes blood counts, bone marrow biopsy findings, and risk scoring. Your hematologist will use all of these together — not the JAK2 result alone — to decide on the most appropriate management for your specific situation.

For most people with polycythemia vera or essential thrombocythemia, initial management focuses on reducing the risk of blood clots and controlling symptoms, with regular blood test monitoring. Treatment intensity is guided by risk category rather than JAK2 status alone.

For patients with myelofibrosis and significant symptoms, your hematologist will discuss whether a JAK inhibitor is appropriate, which drug is the best fit for your situation, and whether stem cell transplantation should be considered.

If JAK2 testing has not yet been performed and you have been told you may have an MPN, it is worth asking your hematologist when the result is expected and how it will influence the next steps in your care.

Questions to ask your doctor

Do I have a JAK2 V617F mutation, a JAK2 exon 12 mutation, or neither — and what does that mean for my diagnosis?
What is my JAK2 allele burden, and what does that number tell us about how the disease is likely to behave?
If my JAK2 result is negative, will CALR and MPL testing be done?
How does my JAK2 result affect my risk of blood clots, and what steps should I take to reduce that risk?
Am I a candidate for a JAK inhibitor, and if so, which one is best suited to my situation?
Will my JAK2 allele burden be monitored over time, and what change in the result would prompt a reassessment of my treatment?
If I have myelofibrosis, should I be assessed for stem cell transplantation?